Cerapedics
Cerapedics is a Westminster, Colorado-based medical device company that develops and commercializes FDA PMA-approved P-15 peptide-enhanced bone graft products (i-FACTOR and PearlMatrix) for cervical and lumbar spinal fusion, sold to spine surgeons and hospitals through direct sales and GPO agreements with Premier Inc. and Vizient.
- Company typePrivate
- Founded2015
- HeadquartersWestminster, United States
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What Cerapedics does
Cerapedics is a privately-held commercial-stage medical device company headquartered in Westminster, Colorado, that develops and commercializes proprietary osteobiologic products for spinal fusion surgery. The company's core technology is the P-15 Osteogenic Cell Binding Peptide, a synthetic 15-amino-acid sequence derived from Type-1 collagen that is bound onto different osteoconductive scaffolds to accelerate bone formation through an attract-attach-activate mechanism. This technology is the basis for two FDA Premarket-Approved Class III drug-device combination products: i-FACTOR, approved in November 2015 for single-level anterior cervical discectomy and fusion (ACDF) and commercially launched in the U.S. in 2016, and PearlMatrix, approved in June 2025 for single-level transforaminal lumbar interbody fusion (TLIF) with expanded indications covering ALIF, PLIF, OLIF, and LLIF approved in January 2026. PearlMatrix is positioned as the first and only bone growth accelerator proven to accelerate lumbar fusion, backed by Level 1 clinical evidence from the ASPIRE IDE study (293 patients across 33 U.S. centers) and six-year i-FACTOR follow-up data showing 98.6% fusion rates.
Cerapedics generates revenue through direct hardware sales of bone graft products to hospitals and surgical centers, sold via a combination of direct sales representatives, local distribution partners, and group purchasing organization agreements with Premier Inc. and Vizient (the latter covering over 65% of U.S. acute care providers). International sales of i-FACTOR products are conducted through distributors, including Surgi-One in Canada, alongside CE Mark and TGA-listed products. The company serves spine surgeons and neurosurgeons performing cervical and lumbar fusion procedures, with named customers including Cleveland Clinic, Washington University School of Medicine, AdventHealth Avista, and Austin Brain and Spine. Pricing is not publicly disclosed, but products target the U.S. spinal bone graft substitution market, where approximately 465,000 fusion cases were performed in 2023.
The company employs approximately 250 people worldwide, has raised over $180 million cumulatively since 2007 across equity and debt rounds, and is led by Chairman and CEO Valeska Schroeder (appointed November 2022). KCK Group has been the lead institutional investor since a $22 million round in 2018, and the company is controlled by KCK Group as parent investor. The company has been recognized with industry awards including the 2018 MedTech Breakthrough Award for Best New Surgical Technology and Denver Post Top Workplaces in 2024 and 2026.
Cerapedics firmographics
Firmographics- Name
- Cerapedics
- Legal name
- Cerapedics Inc.
- Website
- https://cerapedics.com
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Cerapedics is a Westminster, Colorado-based medical device company that develops and commercializes FDA PMA-approved P-15 peptide-enhanced bone graft products (i-FACTOR and PearlMatrix) for cervical and lumbar spinal fusion, sold to spine surgeons and hospitals through direct sales and GPO agreements with Premier Inc. and Vizient.
- Ownership category
- akta.pro rank
Cerapedics industry classification
Industry- Product category
- Spinal Bone Graft Substitutes / Orthobiologics
- NAICS
- Surgical Appliance and Supplies Manufacturing (339113), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM) (HLAHAEAG)
- akta.pro secondary industries
- Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials) (HLAAAGAB), Spine Implants & Motion Preservation (Fusion/Disc/Interspinous) (HLAHAEAC)
Keywords
Where Cerapedics is headquartered
LocationHeadquarters
- HQ city
- Westminster
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Cerapedics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Operations, Personnel, Marketing or Sales, Supply Chain
Revenue model
- i-FACTOR Bone Graft: FDA PMA-approved Class III drug-device combination product for single-level anterior cervical discectomy and fusion (ACDF). Commercialized since 2015/2016 in the U.S. market.
- PearlMatrix Bone Graft: FDA PMA-approved Class III drug-device combination product for single-level transforaminal lumbar interbody fusion (TLIF). Approved June 2025 and now approved for expanded indications including ALIF, PLIF, OLIF, and LLIF approaches.
- International Products: i-FACTOR products available internationally including i-FACTOR Putty and i-FACTOR Flex FR distributed through international markets. Products also available in Canada through distributor Surgi-One.
Go-to-market motion2 records
Distribution channels5 records
Marketing channels7 records
Cerapedics product offering
Product offeringCore offering
Cerapedics develops, manufactures, and commercializes novel osteobiologic bone graft products based on its proprietary P-15 Osteogenic Cell Binding Peptide technology. The company sells FDA PMA-approved Class III drug-device combination products, including i-FACTOR for cervical spine fusion (ACDF) and PearlMatrix for lumbar spine fusion (TLIF, ALIF, PLIF, OLIF, LLIF), targeting spine surgeons and healthcare facilities worldwide.
Differentiator
Problem solved
Functional benefit
Brands
- PearlMatrix: P-15 Peptide Enhanced Bone Graft - FDA-approved Class III drug-device combination product for lumbar spine fusion (TLIF procedures). The first and only bone growth accelerator proven to accelerate lumbar fusion.
- i-FACTOR
Products and services
- i-FACTOR P-15 Peptide Enhanced Bone Graft FDA PMA-approved Class III drug-device combination bone graft using P-15 Osteogenic Cell Binding Peptide technology for single-level anterior cervical discectomy and fusion (ACDF) procedures in patients with degenerative cervical disc disease. Has been used by surgeons since 2015/2016, with six-year IDE follow-up data showing 98.6% fusion rate. Targeted at spine surgeons seeking a clinically proven, cost-effective alternative to autograft for cervical fusion.
- PearlMatrix P-15 Peptide Enhanced Bone Graft FDA PMA-approved Class III drug-device combination bone graft using P-15 Osteogenic Cell Binding Peptide technology bound onto a flexible collagen matrix carrier. Indicated for single-level TLIF and now expanded for all major lumbar interbody surgical approaches (ALIF, PLIF, OLIF, LLIF). The first and only bone growth accelerator demonstrated to accelerate lumbar fusion in Level 1 IDE clinical data, with statistically superior time to fusion versus local autograft. Targeted at spine surgeons treating degenerative disc disease.
- i-FACTOR Flex FR Bone graft substitute utilizing P-15 Osteogenic Cell Binding Peptide technology with purified silk fibers as an inert carrier, providing enhanced cohesion, mechanical properties, and handling characteristics. Sterilized after packaging (terminally sterilized), stored at room temperature, with three-year shelf life, ready to use with no mixing or preparation. Distributed internationally.
- i-FACTOR Putty Bone graft substitute utilizing P-15 Osteogenic Cell Binding Peptide technology. Terminally sterilized after packaging, stored at room temperature, three-year shelf life, ready to use with no mixing or preparation required. Distributed internationally.
- i-FACTOR+ Matrix Next-generation P-15 Peptide Enhanced Bone Graft product approved by Health Canada, distributed in Canada through partner Surgi-One.
Quantifiable outcome
- More than twice as many patients fused at six months vs. local autograft in TLIF procedures
- +4 more outcomes
Companies that use Cerapedics
Customer profileNamed customers4 records
Segments3 records
Ideal customer profiles1 record
Cerapedics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Cerapedics partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core and minor.
- VizientcoreCerapedics announced a supplier agreement with Vizient, the nation's largest provider-driven healthcare performance improvement company, to distribute PearlMatrix P-15 Peptide Enhanced Bone Graft. Vizient's clients include academic medical centers, community hospitals, and integrated health delivery networks serving over 65% of the nation's acute care providers.
- Surgi-OnecoreSurgi-One is the Canadian distributor for i-FACTOR products including i-FACTOR+ Matrix and other Cerapedics bone graft products in Canada.
- DSM MedicalminorGlobal life sciences company partnership mentioned in context of Cerapedics 'embarking on the next phase of commercializing novel osteobiologic products.'
- Premier Inc.coreCerapedics was awarded a group purchasing agreement with Premier Inc. for Breakthrough Technology: Bone Tissue Synthetic Implantable Products. The agreement allows Premier members to access special pricing and terms pre-negotiated for i-FACTOR Peptide Enhanced Bone Graft. Premier unites approximately 3,750 U.S. hospitals and 130,000 other provider organizations.
Scale indicators10 records
Recent moves8 records
Expansion highlights6 records
Cerapedics competitors and assessment
Company assessmentBroad incumbents
- Medtronic: Global spine market leader with Infuse Bone Graft (rhBMP-2) and broader biologics portfolio including cellular bone matrices. Directly competes with Cerapedics in spine fusion bone grafts while serving as a broad incumbent across all spine surgery categories.
- Stryker: Major orthopedic and spine device manufacturer offering OP-1 (BMP-7) bone graft and broader orthobiologics portfolio. Competes with Cerapedics in spine fusion while also serving trauma, joint reconstruction, and other orthopedic segments.
- DePuy Synthes (Johnson & Johnson): Spine and orthobiologics division of J&J offering synthetic bone graft substitutes and demineralized bone matrix products. Competes with Cerapedics in cervical and lumbar fusion bone graft market through established hospital contracts.
Direct peers
- NuVasive: Spine-focused medical device company offering bone graft substitutes and orthobiologics alongside its spinal hardware portfolio. Direct competitor to Cerapedics in cervical and lumbar fusion bone graft market with similar target surgeon customers.
- Orthofix Medical: Spine and orthopedics company offering bone graft substitutes and biologics including Trinity ELITE and fiberFUSE Strip. Competes directly with Cerapedics in spine fusion orthobiologics with overlapping surgeon customer base.
- SeaSpine: Pure-play spine company offering OsteoStrand DBM, OsteoSurge DBM putty, and Accell bone matrix products. Direct competitor to Cerapedics in spine fusion biologics with similar commercial model targeting spine surgeons.
- Bioventus: Orthobiologics company offering bone graft substitutes including SIGNAFUSE and OSTEOAMP. Direct competitor to Cerapedics in spine and orthopedic bone graft markets with established commercial channels.
- Xtant Medical: Spine and orthopedic-focused orthobiologics company offering bone graft substitutes including OsteoVive Plus, 3Demin, and other DBM/synthetic products. Direct competitor to Cerapedics in spine fusion biologics market with comparable customer base.
Emerging players
- Isto Biologics: Orthobiologics company offering Influx bone graft substitute and other cell-based and synthetic bone graft products. Niche competitor in spine and orthopedic fusion markets with partial overlap with Cerapedics' P-15 technology approach.
- LifeNet Health: Non-profit tissue banking organization offering allograft bone graft products including VertiGraft and cellular bone matrices. Competes with Cerapedics in spine fusion through allograft-based alternatives, especially for surgeons preferring biological options.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Cerapedics social profiles
Digital presenceCerapedics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Cerapedics leadership team
Management profileNumber of profiles
Profiles7 records
Cerapedics funding detail
Funding detailFunding overview
Funding rounds13 records
Investors10 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Cerapedics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Cerapedics
What does Cerapedics do?
Cerapedics develops, manufactures, and commercializes novel osteobiologic bone graft products based on its proprietary P-15 Osteogenic Cell Binding Peptide technology. The company sells FDA PMA-approved Class III drug-device combination products, including i-FACTOR for cervical spine fusion (ACDF) and PearlMatrix for lumbar spine fusion (TLIF, ALIF, PLIF, OLIF, LLIF), targeting spine surgeons and healthcare facilities worldwide.
Is Cerapedics a public or private company?
Cerapedics is a private company. It is classified as private equity controlled and is currently operating.
When was Cerapedics founded?
Cerapedics was founded in 2015. It employs 101 to 250 people.
Where is Cerapedics based?
Cerapedics is headquartered in Westminster, United States, in the North America region.
How does Cerapedics make money?
Three revenue lines are on record. i-FACTOR Bone Graft is the primary driver. The others are pearlMatrix Bone Graft and international Products.
Who are Cerapedics's main competitors?
Broad incumbents on record are Medtronic, Stryker and DePuy Synthes (Johnson & Johnson). Direct peers are NuVasive, Orthofix Medical, SeaSpine, Bioventus and Xtant Medical. Emerging players are Isto Biologics and LifeNet Health.
Does Cerapedics have an API?
No public API is recorded for Cerapedics.
What industry is Cerapedics in?
Cerapedics's product category is Spinal Bone Graft Substitutes / Orthobiologics. Its primary akta.pro industry code is HLAHAEAG, Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM), with a secondary code of HLAAAGAB, Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials). Its NAICS code is 339113 and its SIC code is 3842.